Impero (IMPERO) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
27 Jul, 2026Executive summary
Achieved 31% year-over-year ARR growth, reaching DKK 36.9M by Q3 2024, with strong net revenue retention of 109% and record net new ARR.
Added seven new enterprise customers in Q3 and 25 year-to-date, with new product features launched to strengthen market position.
DACH region now contributes 42% of total ARR, with 56% of new ARR YTD from DACH and 57% of ARR from foreign markets.
Positive cash flow from operating activities and a solid cash position of DKK 15M at quarter-end.
Welcomed new Chief Commercial Officer, Mansoor Malik, effective December 1, 2024.
Financial highlights
Q3 2024 revenue was DKK 9.2M, up from DKK 7.1M in Q3 2023; YTD revenue reached DKK 25.8M, a 29% increase.
Gross profit margin remained strong at 96% for Q3 2024, up from 95% year-over-year.
EBITDA improved to DKK -1.6M in Q3 2024 from DKK -2.6M in Q3 2023; for the first nine months, EBITDA was DKK -6.7M, improved from DKK -9.4M.
Operating loss (EBIT) was DKK -8.9M, an improvement from DKK -11.2M year-over-year.
Positive cash flow from operating activities of DKK 0.1M, up from DKK -5.7M last year.
Outlook and guidance
2024 ARR guidance set at DKK 38M to 42M, representing 25% to 38% growth; EBITDA guidance for 2024 is DKK -11M to -9M.
Focus on scaling organization, improving cash burn to ARR ratio, and continued investment in product and commercial expansion.
Key assumptions include partner retention, talent acquisition, customer onboarding, and stable macroeconomic/geopolitical conditions.
Latest events from Impero
- Q2 brought a new administrator dashboard; control testing was targeted for end-July launch as an add-on.IMPERO
Investor update - 2025 brought faster releases and new control tools; entity-level governance and opt-in AI are next.IMPERO
Investor update - Reporting and control workflows expanded, with a control-testing add-on planned for mid-January 2025.IMPERO
Investor update - Control Health reveals activity friction as workflow, analytics and AI capabilities expand.IMPERO
Investor update - ARR up 24% to DKK 50.6M, EBITDA positive, and DACH region ARR grew 35% year-over-year.IMPERO
Q2 2026 - ARR up 15% to DKK 40.7M, revenue up 21%, EBITDA loss narrows, guidance maintained.IMPERO
Q2 2025 - 28% ARR and 29% revenue growth, improved EBITDA, and strong DACH expansion in H1 2024.IMPERO
Q2 2024 - 28% ARR growth, improved EBITDA, and reduced churn set the stage for strong 2025 guidance.IMPERO
Q4 2024 - 24% ARR growth, 27% revenue rise, and strong retention highlight robust Q1 2025 performance.IMPERO
Q1 2025